Summary
The pharmacokinetics of a new Class I antiarrhythmic agent, SUN 1165, has been studied in 32 patients with varying degrees of renal impairment following a single oral dose of 50 mg.
The apparent volume of distribution at steady state was 1.48 1 · kg−1, the absorption rate constant was 2.2 h−1, and plasma protein binding was 26.8% in subjects with normal renal function.
These variables were not altered with renal impairment. More than 60% of SUN 1165 given orally was excreted unchanged via the kidney, both by tubular secretion and glomerular filtration.
The elimination rate constant, the apparent total body clearance and the apparent renal clearance were linearly correlated with the endogenous creatinine clearance. The half-time of elimination was 3.4 h in normal subjects and it was prolonged to 23.7 h in severe renal failure (creatinine clearance below 20 ml · min−1 · 1.48 m−2).
Dosage adjustment of SUN 1165 is necessary in renal failure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hattori Y, Inomata N, Aisaka K, Ishihara T (1986) Electrophysiological actions of N-(2,6-dimethylphenyl)-8-pyrrolizidine-acetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharm 8: 998–1002
Inomata N, Ishihara T, Akaike N (1987) SUN 1165; a new antiarrhythmic Na current blocker in ventricular myocyte of guinea-pig. Comp Biochem Physiol 87c: 237–243
Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T, Satoh F (1988) General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system. Arzneim-Forsch/Drug Res 38 (II): 1398–1409
Hirotsu I, Kihara T, Hattori Y, Hatta M, Hirose N, Ishihara T, Satoh F (1988) General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs. Arzneim- Forsch/Drug Res 38 (II): 1410–1417
Nakashima M, Kanamaru M, Uematsu T, Ohnuma N, Hayashi T, Oh-uchi M, Tsuji A, Morita M (1989) Phase I study of SUN 1165, a novel antiarrhythmic agent. No. 1: single dose study. J Clin Ther Med 5: 661–678
Yokota M, Miyahara T, Enomoto N, Inagaki H, Gotoh S, Hayashi H, Toyama J, Sotohata I (1989) Pharmacokinetics and pharmacodynamics of SUN 1165, a novel antiarrhythmic agent, after administration of a single oral dose. Ther Res 10: 2135–2147
Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1: 126–134
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takabatake, T., Ohta, H., Yamamoto, Y. et al. Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. Eur J Clin Pharmacol 40, 411–414 (1991). https://doi.org/10.1007/BF00265853
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00265853